Google said it would pay its new Chief Financial Officer, Ruth Porat, more than $70 million in the next two years.» Read More
AT&T Inc. said Thursday that the head of its wireless unit, Stan Sigman, was retiring, and it appointed Ralph de la Vega as his successor.
Need proof the Big 3 may be on the verge of doing some good, perhaps even great things? Check out the latest management coup with Ford hiring Jim Farley away from Toyota to become the U.S. automaker's main man running marketing and communications.
Late yesterday an FDA panel of outside experts unanimously recommended the agency approve Medtronic's drug-coated stent called, "Endeavor". Unlike drugs, there is no telegraphed date for an agency decision, but analysts think the FDA will approve the device by the end of the year or early next year.
Virgin Mobile USA, a venture of Sprint Nextel and Richard Branson's Virgin Group, raised $412.5 million on Wednesday, with an initial public offering that priced at the low end of expectations.
Melanoma -- a type of skin cancer -- is the most common form of cancer. It can spread very quickly and the prognosis often is not good. The American Cancer Society estimates that nearly 60,000 new cases of melanoma will be diagnosed this year and more than 8,000 patients will die. You can find out more about it on the ACS's website.
The charitable trust that controls Milton Hershey's fortune and The Hershey Co., the U.S. chocolate company he founded, said Tuesday it is not satisfied with the company's lackluster performance, and is working to improve it.
A man walked into a Giant Eagle supermarket in Pittsburgh Saturday and allegedly tried to change a $1 million bill. The clerk became "suspicious" (really? why is that?), and turned the bill over to the manager. The man with the mill bill got angry and then got arrested. He reportedly had no identification on him. I suspect he was just another disgraced CEO on the run, and that bill was no fake!
An analysis of executive compensation disclosures by 350 companies found it "difficult" to understand how companies used performance targets to set pay levels, according to a U.S. Securities and Exchange Commission staff review released on Tuesday.
As we head into the thick of earnings season some analysts are putting out their preview notes for clients. And a couple of interesting ones about the kings of biotech, Genentech and Amgen, have come into my inbox over the past couple of days. Genentech reports after the bell next Monday, October 15. And Amgen comes out, also after the bell, ten days later on the 25th.
US Treasury debt prices were steady early Tuesday as investors looked ahead to the release of minutes from the Federal Reserve's policy meeting last month when the central bank cut benchmark interest rates.
Facing rising pressure from investors, wireless carrier Sprint Nextel said its chairman and chief executive will leave the company immediately and that 2007 earnings and revenue are likely to be below previous forecasts.
This morning, the world's second biggest drug company, GlaxoSmithKline, announced that Andrew Witty will replace JP Garnier as CEO at the end of next May. It's been known for a while that Garnier would be retiring next year, and the question was who would be tapped to succeed him.
AK Steel Holding said Monday it would create a $663 million healthcare trust as part of a lawsuit settlement with retirees, sending its shares up more than 10 percent.
GlaxoSmithKline has picked Andrew Witty, currently president of its European pharmaceuticals business, to succeed Chief Executive Jean-Pierre Garnier from May 2008, it said on Monday.
You might say Constellation Brands (STZ) is a sparkling company, at least currently. The world's largest winemaker (as well as the manufacturer of Corona and more) is trading up 1.5% after it upped guidance and reported earnings that beat Street estimates. Can Constellation sustain growth or is it likely to fizzle?
Did you see the report from Sanford Bernstein analyst Jeffrey Lindsay this morning, making the case that Yahoo is more valuable broken up than it is as the sum of its pieces? If you're a Yahoo shareholder, you're salivating at the argument. If you're a casual observer, you're wondering whether a plan like this has legs and whether its enough to turn you into a Yahoo shareholder.
“Power Lunch” is in booming North Carolina to focus on housing, financial firms, energy -- and burning rubber at the racetrack. Here's what some of the guests on the program are saying.
Discussing leadership, motivation and career success with Jack Welch, former General Electric chairman & CEO.
General Electric said Thursday it will close a number of lighting plants in Brazil and the U.S., as part of a plan to restructure its consumer and industrial division, potentially cutting more than 1,400 jobs in the process.
Close on the heels of announcing the hiring of a Chief Talent Officer, Pfizer this morning named a new head of Global Research and Development to replace John LaMattina who had earlier said he'd be leaving the drug company. It was on LaMattina's watch that Pfizer's next potential breakout blockbuster drug, torcetrapib for cholesterol, failed in a late-stage clinical trial.